# US 2003/0224455 A1 · Method for the diagnosis of heart diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224455 A1
- Document ID: US20030224455A1
- Status: Published application
- Kind: A1
- Application number: 10/156,352
- Filed: 2002-05-28
- Published: 2003-12-04
- Earliest claimed: 2002-05-28
- Inventors: Mariapia Abbracchio; Flaminio Nicola Cattabeni; Pier Andrea Borea; Katia Varani; Franco Laghi Pasini; Alessandra Camurri
- Web page: https://patentgrep.com/patent/US20030224455A1

## CPC

- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present application discloses a method to diagnose heart diseases, characterised by measuring, in the affected cells, the density of A2A receptors and/or the production of cyclic AMP after stimulation of these cells with A2A receptor agonists. According to the invention, these parameters are used as markers for monitoring the onset, progression and remission of heart diseases. The circulating cells in the patients blood were found to be an adequate model for monitoring, at a peripheral level, the course of these pathologies: this allows the assay to be performed in the way of a simple blood test. The method allows to detect the aforesaid diseases even in their earliest stages, thus allowing the possibility of a timely treatment; the efficacy of any chosen treatments can also be monitored by the present method.

## Claims

### Claim 1

A method to diagnose a heart disease involving haemodynamic deficit, such method comprising the step of measuring, in the patient's affected cells, the density of A2A receptors and/or the production of cyclic AMP induced by a A2A agonist compound.

### Claim 2 (depends on 1)

A method according to claim 1, which is used to monitor the onset, and/or development and/or regression of heart disease, the latter occuring upon heart transplantation and/or specific therapeutic protocols.

### Claim 3 (depends on 1)

A method according to claim 1, which is used to monitor the efficacy of therapeutic interventions aimed at restoring normal haemodynamic functions.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the disease is in its earliest stage of development, in proximity of its complete remission, or in any other situation where its symptoms are hardly visible.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the disease is one among terminal heart failure, myocardial infarction, and cardiac hypofunctionality.

### Claim 6 (depends on 5)

A method according to claim 5, wherein hypofunctionality occurs after heart transplantation.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the affected cells are cells of the heart tissue.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the affected cells are cells of the blood.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the affected cells are chosen from lymphocytes and/or neutrophils.

### Claim 10 (depends on 1)

A method according to claim 1, being performed as follows:
(i) a sample of affected cells is obtained from the patient;
(ii) a part of this sample is tested to assess density of A2A receptors;
(iii) a part of this sample is incubated with an A2A agonist compound and is tested to assess the amount of cyclic AMP produced by these cells;
wherein one between steps (ii) and (iii) is optional and, when both steps (ii) and (iii) are performed, they can take place in any order or simultaneously.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the A2A agonist compound is N-ethylcarboxamidoadenoside (NECA) or any other adenosine analogue able to activate A2A receptors.

### Claim 12 (depends on 1)

A methods according to claim 1, wherein the production of cyclic AMP is assayed with agents acting at post-receptor level, e.s., at G-protein and/or at adenylyl cyclase level.

### Claim 13 (depends on 1)

A method according to claim 1 wherein, during a determined period of time, a series of measurements is taken of A2A receptor density and/or cyclic AMP production, and the respective results are plotted to form a time curve showing the progression of the disease during this period of time.

### Claim 14 (depends on 1)

A diagnostic kit for performing the method of claim 1, comprising means for collecting a cells′ sample, means for measuring the density of A2A receptors and/or the production of cyclic AMP, and instruction about the performance of the method of claim 1.
